{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T23:58:33Z","timestamp":1791503913967,"version":"4.3.4"},"reference-count":31,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2019,3,12]],"date-time":"2019-03-12T00:00:00Z","timestamp":1552348800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Dermatology"],"published-print":{"date-parts":[[2019,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Biologics are efficacious for treating psoriasis vulgaris (PsV) and psoriatic arthritis (PsA), but sometimes must be terminated or changed for various reasons including ineffectiveness or adverse events. To find the optimal choice of biologics for treating psoriasis, we analyzed the real\u2010world data on drug survival and the reason for terminating or switching biologics. Medical records from patients with PsV or PsA, who visited the Department of Dermatology, Fukuoka University Hospital from 2010 to 2017, were analyzed. Two hundred and eleven patients received biologics, and 147 patients (69.7%) were treated with only one biologic, while 64 patients (30.3%) were switched to different products. Frequently used biologics in PsV were ustekinumab (<jats:styled-content style=\"fixed-case\">UST<\/jats:styled-content>), infliximab and adalimumab when calculated by patient\u2010year. Tumor necrosis factor inhibitor (<jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content>i) use decreased while <jats:styled-content style=\"fixed-case\">UST<\/jats:styled-content> and interleukin (<jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>)\u201017 inhibitors increased in newly introduced patients. <jats:styled-content style=\"fixed-case\">UST<\/jats:styled-content> showed the highest survival rate as a first\u2010line drug, but the advantage was lost in the second reagent's group. The major reasons for terminating\/switching biologics were as follows: primary ineffectiveness (26.4%), secondary loss of efficacy (36.5%), patient's preference, including referral to nearby hospital, or stopped visiting (22.6%), side\u2010effects (7.7%), comorbidities (3.4%) and economic burden (2.4%). In PsA patients, <jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content>i are more frequently employed than in PsV patients, although switching to <jats:styled-content style=\"fixed-case\">UST<\/jats:styled-content> or <jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>\u201017 inhibitors showed an increasing trend. Biologic reagents were changed mostly because of primary or secondary loss of efficacy, which affected drug survival. Further research is needed to find the optimal choice of biologics with larger samples at multiple facilities.<\/jats:p>","DOI":"10.1111\/1346-8138.14834","type":"journal-article","created":{"date-parts":[[2019,3,12]],"date-time":"2019-03-12T20:34:58Z","timestamp":1552422898000},"page":"389-398","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Sustainability and switching of biologics for psoriasis and psoriatic arthritis at Fukuoka University Psoriasis Registry"],"prefix":"10.1111","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6725-6893","authenticated-orcid":false,"given":"Bolortuya","family":"Bayaraa","sequence":"first","affiliation":[{"name":"Department of Dermatology Fukuoka University Faculty of Medicine Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8568-4349","authenticated-orcid":false,"given":"Shinichi","family":"Imafuku","sequence":"additional","affiliation":[{"name":"Department of Dermatology Fukuoka University Faculty of Medicine Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,3,12]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/23.4.246"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200304070-00001"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14321"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13439"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67566-6"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.09.010"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60725-4"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60726-6"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60125-8"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314258"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503824"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2015.171"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13343"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13853"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13860"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14454"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14470"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040622317738910"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2017.53.5.2613690"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13785"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.03.008"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.170429"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2016.1242409"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2018.1410133"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.12239"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket187"},{"key":"e_1_2_8_28_1","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/ddg.13516","article-title":"S3 Guideline for the treatment of psoriasis vulgaris, update \u2010 short version part 1 \u2010 systemic treatment","volume":"16","author":"Nast A","year":"2018","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06893.x"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12454"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14965"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39573"}],"container-title":["The Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1346-8138.14834","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.14834","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1346-8138.14834","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.14834","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T17:41:43Z","timestamp":1694367703000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1346-8138.14834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,12]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["10.1111\/1346-8138.14834"],"URL":"https:\/\/doi.org\/10.1111\/1346-8138.14834","archive":["Portico"],"relation":{},"ISSN":["0385-2407","1346-8138"],"issn-type":[{"value":"0385-2407","type":"print"},{"value":"1346-8138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,12]]},"assertion":[{"value":"2018-12-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}